Keryx Biopharma (KERX) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St futures kick off September under pressure as yields, oil prices rise
- Oil rises as renewed US-Iran strikes stoke supply fears
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
BTIG Cuts Keryx Biopharmaceuticals (KERX) to Sell
August 6, 2015 10:01 AM EDTBTIG earlier downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Neutral to Sell with a price target of $3.50. The change follows Q2 results. Analyst Hartaj Sing pointed out revenue weakness.
"We are downgrading Keryx from a Neutral to a Sell with a $3.50 price target after the... More
Keryx Biopharmaceuticals (KERX) PT Cut to $22 at Brean Capital Following Q2; Upside Seen Over 200%
August 5, 2015 12:06 PM EDTBrean Capital analyst Jonathan Aschoff lowered his price target on Keryx Biopharmaceuticals (NASDAQ: KERX) to $22.00 (from $26.00) following Q2 results but maintained a Buy rating as the new price target still suggests 224% upside from current levels. The analyst expects more meaningful Auryxia sales to come in 2H15.
Aschoff commented, "Keryx reported 2Q15 total revenue of $2.5 million, versus consensus of $2.9 million, but we expect more... More
